Los Angeles, California (PRWEB) March 27, 2013
The Los Angeles Minimally Invasive Spine Institute today announced that the Institute is among the first in Southern California to conduct a clinical trial using a unique form of minimally invasive spine surgery to treat patients suffering from back pain. The trial studies the use of a spinal stabilization system and is the first of its kind to assess the use of an implanted “shock absorber” to treat back pain. The principal investigator on the study is Dr. George Rappard, a Neurointerventional Surgeon, specializing in minimally invasive spine surgery and spinal pain management.
The Device for Intervertebral Assisted Motion (DIAM)™ is a medical device designed to relieve back pain caused by lumbar degenerative disease and offers a minimally invasive alternative to traditional spinal fusion. The DIAM™ device is implanted between the spinous processes through a small skin incision. Once in place, the device can act as a shock absorber, reducing stress on the surrounding spine. This could result in pain relief and a return to a more active lifestyle.
In the U.S., back pain is the leading cause of disability in people under 45 and affects 31 million people at any given time. Currently, the surgical treatment of back pain involves a fusion, a very extensive surgery with only about a 60% success rate. The DIAM™ device only requires a small incision to implant and may result in an out-patient treatment for those with severe back pain.
“The DIAM™ trial offers phenomenal possibilities in that, for the first time, we may have an important minimally invasive treatment option for back pain that we can extend to a broader number of patients. We are very excited to participate in such a potentially ground breaking clinical study,” said Dr. Rappard.
The clinical trial is sponsored by Medtronic, a global leader in medical technology. Medtronic has a history of creating novel technologies that treat chronic diseases in new ways, and has an extensive history of supporting clinical device trials.
The trial is designed to assess the success of the DIAM™ device in relieving back pain and disability. Patients will be randomized into two groups, an investigational group receiving the DIAM™ implant and a control group, receiving medications, physical therapy and pain injections. Patients in the control group may cross over into the DIAM™ group if they fail their prescribed therapy.
To learn more about the treatment of back and neck pain at the Los Angeles Minimally Invasive Spine Institute or to see if you qualify for our research studies and minimally invasive spine surgery options, visit us on the web at http://www.LAMISinstitute.com or call us at 323-857-5300. To learn more about the DIAM™ trial, visit http://clinicaltrials.gov/show/NCT00456378